Xenocor announces a series A-2 round investment by Growing Impact Ventures to enable increased production in response to growing market demand for the Xenoscope™, the first single–use, fog-free, HD laparoscopic imaging system.
Xenocor notes the Xenoscope provides both clinical and financial advantages that benefit surgeons, staff, healthcare facilities and most importantly, patients. It is well positioned to replace expensive, inflexible legacy technologies making laparoscopic surgery possible virtually anywhere.
“We strictly invest in companies that could have a dramatic impact on the health of human beings worldwide. These technologies must have the capacity to scale globally, as well as have the potential to drive positive societal transformation,” said John Evey, Managing Director of Growing Impact Ventures. “The Xenoscope is such a product. Not only is it compact and portable, but it also delivers technological advances on several fronts, making it possible for high quality laparoscopic surgery to be done anywhere. This means in a hospital, in an office, in cities and in the outback.”
The Xenoscope
The innovative technologies of the Xenoscope offer vastly improved image quality (HD and fog-free), eliminate cross-contamination, reduce technical complications and operation room downtimes. There are no large capital expenditures or expensive long-term maintenance contracts, making the Xenoscope accessible to markets of varying size.
“The advanced features of the Xenoscope have the potential to dramatically upend laparoscopic surgical processes and expenditures in countries which spend an inordinate amount of resources on healthcare. But equally important, these new capabilities can leap-frog over legacy technologies to quickly deliver a higher standard of care to those in countries which desperately need it,” said Evan Kelso, CEO of Xenocor. “Our focus now is to increase production and respond to the demand we are experiencing. This investment from Growing Impact Ventures facilitates a swift response.”